Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
signed informed consent form
For Cohort 1, HIV-infected subjects receiving nevirapine 200 mg twice-daily and 2 to 3 NRTIs for at least 6 weeks
For Cohort 2, HIV-infected subjects receiving atazanavir 300 mg and ritonavir 100 mg once-daily and 2 to 3 NRTIs for at least 6 weeks
Have had 2 measurements of plasma HIV RNA of \<400 copies/mL. The first test being 6 to 16 weeks prior and the second being within 3 weeks prior to Day 1
Have CD4 cell count \>=200 cells/mm3
Body Mass Index of 18 to 35 kg/m2.
Men and women, ages 18 to 55.
You may not be if
Women who are pregnant or breastfeeding
Presence of a newly diagnosed HIV-related opportunistic infection or CD4 cell count \<200 cell/mm3 within the previous 6 months.
Any significant acute or chronic medical illness, unless stable or controlled by a non-prohibited medication.
History of virologic failure on an antiretroviral regimen.
